Telemetry Investments’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Telemetry Investments’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$903K	Buy	483,000 +138,000	+40%	+$344K	1.43%	14
2022 Q3	$887K	Sell	345,000 -150,000	-30%	-$373K	1.14%	23
2022 Q2	$955K	Buy	495,000 +132,000	+36%	+$288K	1.13%	16
2022 Q1	$1.08M	Buy	363,000 +100,721	+38%	+$379K	1.7%	10
2021 Q4	$1.18M	Buy	262,279 +19,765	+8%	+$93.8K	1.52%	11
2021 Q3	$1.18M	Buy	242,514 +75,022	+45%	+$413K	1.59%	14
2021 Q2	$1.14M	Sell	167,492 -3,778	-2%	-$30.5K	1.57%	17
2021 Q1	$1.21M	Sell	171,270 -23,519	-12%	-$169K	1.37%	21
2020 Q4	$1.22M	Buy	194,789 +39,416	+25%	+$232K	2.06%	15
2020 Q3	$841K	Buy	155,373 +90,873	+141%	+$450K	1.83%	20
2020 Q2	$337K	Buy	+64,500	New	+$286K	0.92%	44
2019 Q1	–	Sell	-22,000	Closed	-$113K	–	154
2018 Q4	$113K	Buy	+22,000	New	+$167K	0.07%	121
2018 Q2	–	Sell	-40,977	Closed	-$533K	–	167
2018 Q1	$533K	Buy	+40,977	New	+$610K	0.2%	73

Other funds holding PRTK

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Telemetry Investments's PRTK Position: Q4 2022 in Review

Telemetry Investments increased its Paratek Pharmaceuticals, Inc. (PRTK) stake by 40% in Q4 2022, buying an estimated $344K and bringing the position to 483,000 shares worth $903K. The position accounts for 1.43% of the portfolio, ranked #14.

Telemetry Investments first reported a position in PRTK in Q1 2018 and has held it in 13 quarters since. The position peaked at $1.22M in Q4 2020. 76 funds tracked by Wall St. Rank hold PRTK as of Q4 2022.

Telemetry Investments held 483,000 shares of Paratek Pharmaceuticals, Inc. worth $903K as of Q4 2022.
Telemetry Investments bought 138,000 Paratek Pharmaceuticals, Inc. shares in Q4 2022, an estimated $344K.
Paratek Pharmaceuticals, Inc. made up 1.43% of Telemetry Investments's portfolio in Q4 2022, its #14 holding.
Telemetry Investments first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and has held it in 13 quarters since.
Telemetry Investments's Paratek Pharmaceuticals, Inc. position peaked at $1.22M in Q4 2020.
76 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2022.

Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.